Millipore Sigma Vibrant Logo

OP102 Anti-von Hippel-Lindau (VHL) Mouse mAb (Ig33)

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
OP102
  
Retrieving price...
Price could not be retrieved
Minimum Quantity is a multiple of
Maximum Quantity is
Upon Order Completion More Information
You Saved ()
 
—
Request Pricing
—
Limited Availability Limited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

       

      Contact Customer Service

      Overview

      Replacement Information

      Key Spec Table

      Host
      M
      Description
      Overview

      This product has been discontinued.





      Recognizes the ~30 kDa von Hippel-Lindau (VHL) protein in prostate, lung, colon, breast, bladder or carcinoma tissue.
      Catalogue NumberOP102
      Brand Family Calbiochem®
      References
      ReferencesCorliss, C.L., et al. 1997.Human Pathology 28, 459.
      Lee, S., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 1770.
      Siemeister, G., et al. 1996. Cancer Res. 56, 2299.
      Tsuchiya, H., et al. 1996. Cancer Res. 56, 2881.
      Chen, F., et al. 1995. Cancer Res. 55, 4804.
      Duan, D.R., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 6459.
      Duan, D.R., et al. 1995. Science 269, 1402.
      Iliopoulos, O., et al. 1995. Nat. Med. 1, 822.
      Kishida, T., et al. 1995. Cancer Res. 55, 4544.
      Kley, N., et al. 1995. Glia 15, 297.
      Wizigmann-Voos, S., et al. 1995. Cancer Res. 55, 1358.
      Product Information
      FormLiquid
      FormulationIn 10 mM PBS, 0.2% BSA, pH 7.4.
      Positive controlProstate, kidney, lung, colon, breast, bladder, or thyroid carcinoma tissue
      Preservative≤0.1% sodium azide
      Applications
      Application ReferencesOriginal Clone Kibel, A., et al. 1995. Science 269, 1444.
      Key Applications Immunoblotting (Western Blotting)
      Paraffin Sections
      Application NotesImmunoblotting (1-2 µg/ml)
      Paraffin Sections (2-4 µg/ml; heat pre-treatment required, see comments)
      Application CommentsPrior to staining formalin-fixed, paraffin-embedded tissue sections, boil the tissue in 1 mM EDTA, pH 8.0, for 10-20 min, followed by cooling at room temperature for 20 min. Antibody should be titrated for optimal results in individual systems.
      Biological Information
      Immunogena recombinant fusion protein consisting of amino acids 1-213 of human VHL
      ImmunogenHuman
      CloneIg33
      HostMouse
      IsotypeIgG₁
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Blue Ice Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial use, aliquot and freeze (-20°C) for long-term storage.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      OP102 0

      Documentation

      Anti-von Hippel-Lindau (VHL) Mouse mAb (Ig33) SDS

      Title

      Safety Data Sheet (SDS) 

      Anti-von Hippel-Lindau (VHL) Mouse mAb (Ig33) Certificates of Analysis

      TitleLot Number
      OP102

      References

      Reference overview
      Corliss, C.L., et al. 1997.Human Pathology 28, 459.
      Lee, S., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 1770.
      Siemeister, G., et al. 1996. Cancer Res. 56, 2299.
      Tsuchiya, H., et al. 1996. Cancer Res. 56, 2881.
      Chen, F., et al. 1995. Cancer Res. 55, 4804.
      Duan, D.R., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 6459.
      Duan, D.R., et al. 1995. Science 269, 1402.
      Iliopoulos, O., et al. 1995. Nat. Med. 1, 822.
      Kishida, T., et al. 1995. Cancer Res. 55, 4544.
      Kley, N., et al. 1995. Glia 15, 297.
      Wizigmann-Voos, S., et al. 1995. Cancer Res. 55, 1358.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision09-July-2007 RFH
      ApplicationImmunoblotting (1-2 µg/ml)
      Paraffin Sections (2-4 µg/ml; heat pre-treatment required, see comments)
      DescriptionPurified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with NS1 mouse myeloma cells (see application references). Recognizes the ~30 kDa von Hippel-Lindau protein (VHL).
      BackgroundVon Hippel-Lindau disease is a rare tumor syndrome that is characterized by cerebellar and spinal hemangioblastomas and retinal angiomas. Molecular studies suggest that VHL is a tumor suppressor gene, which is inactivated or mutated in von Hippel-Lindau disease as well as in clear-cell renal carcinomas (RCC). The gene is affected in both hereditary and in sporadic tumors. In clear-cell renal carcinomas there is loss of function of both copies of the gene suggesting a role in proliferation control. This hypothesis is borne out by the observation that transfection of the wild type protein will inhibit cell growth. Initially identified in 1993, the VHL protein has a bipartite localization, it is found localized to the cytoplasm in densely cultured cells but in the nucleus in sparse cell cultures. The primary functional target of VHL protein is the transcription elongation complex in particular, the elongin proteins B and C which bind in vitro and in vivo to a short, colinear region of the VHL protein that is frequently mutated in human tumors. In addition to the elongins, VHL has been shown to bind to other proteins including the HIV tat-binding protein, filamin and VBP-1, and two other VHL binding proteins, p14 (p16) and p10 (p9). More recently, VHL has been shown to control VEGF expression in several different tumors, affecting primarily the splice variants VEGF121 and VEGF165.
      HostMouse
      Immunogen speciesHuman
      Immunogena recombinant fusion protein consisting of amino acids 1-213 of human VHL
      CloneIg33
      IsotypeIgG₁
      Specieshuman
      Positive controlProstate, kidney, lung, colon, breast, bladder, or thyroid carcinoma tissue
      FormLiquid
      FormulationIn 10 mM PBS, 0.2% BSA, pH 7.4.
      Concentration Label Please refer to vial label for lot-specific concentration
      Preservative≤0.1% sodium azide
      CommentsPrior to staining formalin-fixed, paraffin-embedded tissue sections, boil the tissue in 1 mM EDTA, pH 8.0, for 10-20 min, followed by cooling at room temperature for 20 min. Antibody should be titrated for optimal results in individual systems.
      Storage Avoid freeze/thaw
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial use, aliquot and freeze (-20°C) for long-term storage.
      Toxicity Standard Handling
      ReferencesCorliss, C.L., et al. 1997.Human Pathology 28, 459.
      Lee, S., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 1770.
      Siemeister, G., et al. 1996. Cancer Res. 56, 2299.
      Tsuchiya, H., et al. 1996. Cancer Res. 56, 2881.
      Chen, F., et al. 1995. Cancer Res. 55, 4804.
      Duan, D.R., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 6459.
      Duan, D.R., et al. 1995. Science 269, 1402.
      Iliopoulos, O., et al. 1995. Nat. Med. 1, 822.
      Kishida, T., et al. 1995. Cancer Res. 55, 4544.
      Kley, N., et al. 1995. Glia 15, 297.
      Wizigmann-Voos, S., et al. 1995. Cancer Res. 55, 1358.
      Application referencesOriginal Clone Kibel, A., et al. 1995. Science 269, 1444.